Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-20
    E.g., 2018-09-20

Archive Search

6 results
12:00 AM, Feb 03, 2014  |  BioCentury | Product Development

Spies graduate

NASDAQ:AMGN) Trebananib (AMG 386) Recombinant Fc-peptide fusion protein (peptibody) targeting angiopoietin 1 (ANG1; ANGPT1) and angiopoietin 2
ANG2; ANGPT2) Entered Mar 2010; status undisclosed Amgen Inc. (NASDAQ:AMGN) Ganitumumab (AMG 479) Human mAb targeting …
12:00 AM, Oct 17, 2011  |  BioCentury | Product Development

Tremelimumab, take three

and IGF-2 ; MEDI-551 , an anti- CD19 mAb; and MEDI-3617 , a mAb against angiopoietin 2
ANG2 ). All are in Phase I testing for cancer. BMS has its own combination …
12:00 AM, Jun 21, 2010  |  BioCentury | Product Development

Targeting ovarian

a recombinant Fc-peptide fusion protein (peptibody) targeting angiopoietin 1 ( ANG1 ; ANGPT1 ) and angiopoietin 2
ANG2 ; ANGPT2 ). ANG1 and ANG2 interact with tyrosine kinase receptor 2 (Tie2) to …
remodeling. ANG1 promotes vessel stabilization by increasing endothelial junctions and pericyte coverage of endothelial cells. ANG2
12:00 AM, Mar 22, 2010  |  BioCentury | Product Development

Spies plot revolution

related apoptosis-inducing ligand receptor 2 (TRAIL-R2) AMG 386 Amgen Inc. (NASDAQ:AMGN) Angiopoietin 1 (ANG1; ANGPT1); angiopoietin 2
ANG2; ANGPT2) Figitumumab Pfizer Inc. (NYSE:PFE) Insulin-like growth factor-1 receptor (IGF1R; CD221) Neratinib (HKI-272) Pfizer Inc …
12:00 AM, Feb 23, 2009  |  BioCentury | Product Development

Pipeline proliferation

against EGFR 1 (HER1) (ErbB1) Recombinant Fc-peptide fusion protein(peptibody) targeting angio- poietin 1 (Ang1) and Ang2
12:00 AM, Feb 23, 2009  |  BioCentury | Product Development

Amgen's cancer trove

sarcoma. AMG 386 is a peptibody (Fc-peptide fusion protein) that targets the angiopoietins Ang1 and Ang2
neovascularization via the Tie2 receptor in a pathway that is separate from VEGF. Amgen believes Ang1/Ang2